Attended by specialists in the digestive disease area, the 9th Chinese H. pylori and Digestive Diseases Forum was held in Guangzhou on August 8-9, 2014. This conference provided a platform for world and national leading experts in the digestive disease area to present research, exchange ideas and discuss collaborative opportunities. TenNor’s Founder and CEO, Dr. Zhenkun Ma was invited to speak at the Forum and presented a seminar titled “New Drugs for HP Eradication – Need and Reality.” The talk was well received. Professor Hu Fulian, Chairwoman of the conference commented: "This speech is one of the highlights of the Forum. It is totally consistent with the general theme of the conference: Cooperation, Exploration, Innovation and Truth-seeking." Vice President Erdong Hua and Investment Manager Xuepeng Guan from Frontline Bioventures attended this Forum.

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late stage of clinical development, targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com